All In Biotech

Drug Trial Radar · NCT05184088

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

244

Actual

Start

Jan 13, 2023

Primary completion

Apr 21, 2026

Study completion May 5, 2026

Sponsor

Lead sponsor
Lantheus Germany GmbHIndustry
Sponsor type
Industry
Collaborators
pharmtrace klinische Entwicklung GmbH
First posted
Jan 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.

Conditions

  • Cardiac Amyloidosis
  • AL Amyloidosis
  • ATTR Amyloidosis

Interventions

  • [18F]florbetabenDrug

    All enrolled patients will undergo \[18F\]florbetaben PET imaging.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis.Time frame: Up to 12 weeks

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • St Luke's Hospital

    Kansas City, Kansas

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Augsburg

    Augsburg, Germany

  • Charite Berlin

    Berlin, Germany

  • University of Essen

    Essen, Germany

  • HOPA Hamburg

    Hamburg, Germany

  • University of Heidelberg

    Heidelberg, Germany

  • University of Würzburg

    Würzburg, Germany

  • Hospital University Bellvitge

    Barcelona, Spain

  • Hospital University Puerta de Hierro

    Madrid, Spain

  • Clínica Universidad de Navarra

    Pamplona, Spain

  • University of Salamanca

    Salamanca, Spain

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.